Ocugen to Present Modifier Therapy Updates at April Conferences, BLA Submission Plans
Ocugen will spotlight its gene-agnostic modifier therapy platform at two industry conferences: Innovation on the Island in Puerto Rico (April 27-29) and Cell & Gene Meeting on the Mediterranean in Rome (April 28-30). Executives will discuss near-term catalysts, including a planned BLA submission for OCU400 later this year.
1. Presentation Schedule and Locations
Dr. Shankar Musunuri and Abhi Gupta will present at Oppenheimer’s 3rd Annual Innovation on the Island Biotech Summit in Rio Grande, Puerto Rico, from April 27 to 29, 2026, with Dr. Musunuri speaking at 8:20 a.m. AST on April 28. Gupta will present at the Cell & Gene Meeting on the Mediterranean in Rome on April 28 at 4:30 p.m. CEST.
2. Leadership and Platform Focus
Musunuri, Ocugen’s CEO and co-founder, and Gupta, EVP of Commercial and Business Development, will showcase the company’s modifier gene therapy platform and gene-agnostic approach designed to address all mutations related to major blindness diseases.
3. Near-Term Catalysts and Regulatory Plans
Ocugen executives will outline near-term catalysts, including a planned BLA submission for OCU400 later this year, positioning the company for potential commercialization of its gene therapy for blindness diseases.